display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
combined BRAF-MEK inhibitors
trametinib plus dabrafenib BRF113928

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons